hydrocodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1386 125-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydrocodone
  • dihydrocodeinone
  • hydrocodon
  • multacodin
  • hydrocodone bitartrate
  • hydrocodone polistirex
Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.
  • Molecular weight: 299.37
  • Formula: C18H21NO3
  • CLOGP: 1.13
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 38.77
  • ALOGS: -2.57
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 62.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.15 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 23, 1943 FDA ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 909.04 10.56 867 54115 132966 56104119
Cholecystitis chronic 455.75 10.56 212 54770 9536 56227549
Toxicity to various agents 361.05 10.56 723 54259 223841 56013244
Drug hypersensitivity 275.13 10.56 735 54247 274470 55962615
Cardio-respiratory arrest 250.14 10.56 289 54693 55032 56182053
Emotional distress 192.24 10.56 188 54794 29575 56207510
Cholelithiasis 176.39 10.56 205 54777 39259 56197826
Respiratory arrest 173.16 10.56 180 54802 30445 56206640
Injury 170.63 10.56 249 54733 59602 56177483
Contraindicated product administered 162.97 10.56 4 54978 186282 56050803
Drug abuse 162.70 10.56 260 54722 67350 56169735
Gallbladder disorder 162.34 10.56 135 54847 17199 56219886
Anxiety 156.72 10.56 479 54503 192693 56044392
Deep vein thrombosis 139.33 10.56 261 54721 76716 56160369
Maternal exposure during pregnancy 130.23 10.56 16 54966 189537 56047548
Rheumatoid arthritis 124.97 10.56 114 54868 382490 55854595
Drug intolerance 122.03 10.56 53 54929 264765 55972320
Synovitis 117.47 10.56 11 54971 161294 56075791
Depression 115.03 10.56 412 54570 179705 56057380
Hand deformity 113.54 10.56 4 54978 134488 56102597
Glossodynia 112.08 10.56 10 54972 152448 56084637
Systemic lupus erythematosus 110.47 10.56 21 54961 180057 56057028
Intentional product misuse 109.01 10.56 187 54795 51317 56185768
Infusion related reaction 102.45 10.56 38 54944 208893 56028192
Treatment failure 102.15 10.56 21 54961 170371 56066714
Off label use 101.58 10.56 248 54734 555932 55681153
Biliary dyskinesia 99.26 10.56 49 54933 2514 56234571
Pericarditis 83.23 10.56 6 54976 108917 56128168
Lower respiratory tract infection 83.10 10.56 8 54974 114786 56122299
Gallbladder injury 79.06 10.56 34 54948 1266 56235819
Pulmonary embolism 77.89 10.56 256 54726 106868 56130217
Joint swelling 77.25 10.56 102 54880 289698 55947387
Drug ineffective 75.89 10.56 557 54425 918432 55318653
Cardiac arrest 75.49 10.56 220 54762 86094 56150991
Wound 73.69 10.56 22 54960 138782 56098303
Pain 72.03 10.56 974 54008 662210 55574875
Death 69.00 10.56 569 54413 340857 55896228
Drug withdrawal syndrome 67.10 10.56 103 54879 25754 56211331
Discomfort 65.82 10.56 28 54954 141733 56095352
Accidental death 62.08 10.56 32 54950 1800 56235285
Accidental overdose 59.53 10.56 86 54896 20375 56216710
Product use issue 57.62 10.56 58 54924 185983 56051102
Drug dependence 57.40 10.56 89 54893 22444 56214641
Inadequate analgesia 55.91 10.56 34 54948 2637 56234448
Arthropathy 55.91 10.56 68 54914 200207 56036878
Rheumatoid factor positive 55.15 10.56 3 54979 69057 56168028
Overdose 55.08 10.56 227 54755 105603 56131482
Rash 53.45 10.56 274 54708 492773 55744312
Hepatic enzyme increased 51.29 10.56 55 54927 171329 56065756
C-reactive protein increased 50.80 10.56 8 54974 78676 56158409
Helicobacter infection 50.73 10.56 6 54976 73262 56163823
Back pain 48.77 10.56 397 54585 236773 56000312
Abdominal discomfort 48.60 10.56 126 54856 277148 55959937
Exposure during pregnancy 47.60 10.56 38 54944 136304 56100781
Anhedonia 46.80 10.56 53 54929 9861 56227224
Drug abuser 46.42 10.56 31 54951 2828 56234257
Gallbladder hypofunction 42.94 10.56 17 54965 511 56236574
Therapeutic product effect decreased 41.75 10.56 63 54919 169389 56067696
Neutropenia 41.75 10.56 56 54926 158111 56078974
Biliary colic 41.56 10.56 31 54951 3371 56233714
Coronary artery disease 40.97 10.56 92 54890 30704 56206381
Nasopharyngitis 40.58 10.56 98 54884 220861 56016224
Muscle injury 39.78 10.56 3 54979 52497 56184588
Cholecystitis 39.57 10.56 59 54923 14376 56222709
Condition aggravated 39.42 10.56 188 54794 344710 55892375
Mental status changes 39.13 10.56 102 54880 37399 56199686
Hypersensitivity 37.34 10.56 127 54855 256281 55980804
Alopecia 35.89 10.56 156 54826 293302 55943783
Scar 35.79 10.56 52 54930 12381 56224704
Insomnia 35.10 10.56 313 54669 191547 56045538
Cerebrovascular accident 34.86 10.56 190 54792 99080 56138005
Folliculitis 34.57 10.56 6 54976 54973 56182112
Respiratory depression 34.34 10.56 51 54931 12384 56224701
Chest pain 32.87 10.56 306 54676 189491 56047594
Cholesterosis 31.78 10.56 13 54969 426 56236659
Acute lung injury 31.61 10.56 19 54963 1443 56235642
Swelling 31.46 10.56 124 54858 239647 55997438
Febrile neutropenia 31.42 10.56 34 54948 105511 56131574
Infection 31.34 10.56 96 54886 200110 56036975
Gallbladder cholesterolosis 31.27 10.56 15 54967 722 56236363
Pyrexia 30.97 10.56 261 54721 418512 55818573
Nausea 29.98 10.56 966 54016 763212 55473873
Muscle spasms 29.86 10.56 233 54749 137138 56099947
Intervertebral disc protrusion 27.95 10.56 64 54918 21630 56215455
Sleep disorder due to general medical condition, insomnia type 26.66 10.56 5 54977 43333 56193752
Feeling abnormal 26.53 10.56 222 54760 133380 56103705
Musculoskeletal stiffness 26.46 10.56 72 54910 155935 56081150
Drug screen positive 26.41 10.56 24 54958 3440 56233645
Dependence 26.20 10.56 19 54963 1978 56235107
Intervertebral disc degeneration 25.34 10.56 48 54934 14206 56222879
Poisoning 25.11 10.56 45 54937 12768 56224317
Pain in extremity 24.38 10.56 417 54565 297014 55940071
Mental disorder 23.40 10.56 63 54919 23541 56213544
Uterine perforation 22.92 10.56 30 54952 6475 56230610
Ill-defined disorder 22.80 10.56 20 54962 68523 56168562
Migraine 22.15 10.56 153 54829 86644 56150441
Electrocardiogram QT prolonged 21.99 10.56 13 54969 54575 56182510
Cardiac failure 21.71 10.56 29 54953 82064 56155021
Dehydration 21.71 10.56 244 54738 158581 56078504
Product use in unapproved indication 21.69 10.56 68 54914 140754 56096331
Thrombocytopenia 20.82 10.56 66 54916 136158 56100927
Thrombosis 20.35 10.56 113 54869 59314 56177771
Chronic obstructive pulmonary disease 19.55 10.56 109 54873 57306 56179779
Peripheral swelling 19.31 10.56 142 54840 234584 56002501
Abnormal dreams 19.05 10.56 34 54948 9615 56227470
Cholecystectomy 18.97 10.56 34 54948 9650 56227435
Renal impairment 18.92 10.56 31 54951 80682 56156403
Memory impairment 18.90 10.56 147 54835 86410 56150675
Cholecystitis acute 18.48 10.56 29 54953 7387 56229698
Liver injury 18.26 10.56 9 54973 41839 56195246
Gamma-glutamyltransferase increased 18.19 10.56 4 54978 31001 56206084
Back injury 18.11 10.56 30 54952 7996 56229089
Withdrawal syndrome 18.02 10.56 49 54933 18413 56218672
Gastrooesophageal reflux disease 17.96 10.56 141 54841 83116 56153969
Leukopenia 17.82 10.56 26 54956 70914 56166171
Respiratory muscle weakness 17.49 10.56 6 54976 119 56236966
Interstitial lung disease 17.40 10.56 18 54964 57045 56180040
Hepatic function abnormal 17.40 10.56 6 54976 34552 56202533
Purpura senile 17.24 10.56 9 54973 520 56236565
Tarsal tunnel syndrome 17.08 10.56 9 54973 530 56236555
Abortion spontaneous 16.82 10.56 11 54971 43742 56193343
Hepatocellular injury 16.44 10.56 3 54979 26511 56210574
Lactic acidosis 16.36 10.56 7 54975 35339 56201746
Road traffic accident 16.20 10.56 62 54920 27865 56209220
Tooth loss 16.09 10.56 25 54957 6312 56230773
Fear 16.01 10.56 41 54941 14867 56222218
Peptic ulcer 16.00 10.56 20 54962 4124 56232961
Device expulsion 15.83 10.56 5 54977 30444 56206641
Drug interaction 15.79 10.56 130 54852 209625 56027460
Accidental poisoning 15.59 10.56 9 54973 634 56236451
Emotional disorder 15.54 10.56 36 54946 12259 56224826
Myocardial infarction 15.19 10.56 148 54834 92722 56144363
Blister 15.11 10.56 55 54927 108832 56128253
Psoriatic arthropathy 15.06 10.56 31 54951 73977 56163108
Toxic leukoencephalopathy 14.99 10.56 9 54973 682 56236403
Stomatitis 14.87 10.56 64 54918 120746 56116339
Abdominal pain 14.85 10.56 344 54638 258461 55978624
Cholestasis 14.76 10.56 4 54978 26909 56210176
Blood pressure systolic increased 14.72 10.56 11 54971 40825 56196260
Fall 14.72 10.56 455 54527 357055 55880030
Neck injury 14.63 10.56 13 54969 1810 56235275
Pulmonary infarction 14.61 10.56 15 54967 2497 56234588
Lumbosacral plexopathy 14.51 10.56 3 54979 6 56237079
Hypoaesthesia 14.47 10.56 206 54776 141285 56095800
Red blood cell sedimentation rate increased 14.36 10.56 9 54973 36614 56200471
Impaired healing 14.03 10.56 41 54941 86800 56150285
Extradural haematoma 14.03 10.56 12 54970 1588 56235497
Vestibular disorder 13.84 10.56 11 54971 1314 56235771
Hyperlipidaemia 13.79 10.56 44 54938 18065 56219020
Septic shock 13.67 10.56 24 54958 60811 56176274
Nervousness 13.35 10.56 60 54922 28955 56208130
Product complaint 13.32 10.56 33 54949 11727 56225358
Neuralgia 13.25 10.56 52 54930 23643 56213442
Chronic kidney disease 13.11 10.56 78 54904 41978 56195107
Osteonecrosis 13.02 10.56 51 54931 23164 56213921
Cardiac failure congestive 13.01 10.56 137 54845 87583 56149502
Drug tolerance 12.98 10.56 22 54960 5972 56231113
Major depression 12.82 10.56 25 54957 7559 56229526
Drug-induced liver injury 12.79 10.56 9 54973 34453 56202632
Rotator cuff syndrome 12.63 10.56 33 54949 12110 56224975
General physical health deterioration 12.51 10.56 106 54876 169904 56067181
Erythema 12.50 10.56 95 54887 155844 56081241
Resorption bone increased 12.25 10.56 10 54972 1240 56235845
Nail growth abnormal 12.06 10.56 7 54975 498 56236587
Hyponatraemia 12.03 10.56 55 54927 102084 56135001
Blood pressure fluctuation 12.01 10.56 13 54969 40347 56196738
Therapeutic product effect incomplete 11.96 10.56 58 54924 105973 56131112
Crying 11.94 10.56 47 54935 21393 56215692
Psychological trauma 11.87 10.56 9 54973 1003 56236082
Restless legs syndrome 11.85 10.56 40 54942 16907 56220178
Intestinal ischaemia 11.85 10.56 23 54959 6932 56230153
Muscle tightness 11.84 10.56 30 54952 10806 56226279
Transverse sinus thrombosis 11.81 10.56 7 54975 518 56236567
Wheezing 11.71 10.56 36 54946 74990 56162095
Tendon disorder 11.71 10.56 20 54962 5465 56231620
Intervertebral disc disorder 11.70 10.56 18 54964 4508 56232577
Compression fracture 11.69 10.56 21 54961 5968 56231117
Muscle atrophy 11.64 10.56 22 54960 6499 56230586
Altered state of consciousness 11.58 10.56 4 54978 23017 56214068
Fat intolerance 11.58 10.56 3 54979 21 56237064
Hyperkalaemia 11.49 10.56 20 54962 50845 56186240
Chronic fatigue syndrome 11.46 10.56 9 54973 1056 56236029
Aortic valve incompetence 11.37 10.56 20 54962 5592 56231493
Unresponsive to stimuli 11.31 10.56 61 54921 31664 56205421
Irritable bowel syndrome 11.29 10.56 32 54950 68426 56168659
Spinal osteoarthritis 11.26 10.56 36 54946 14800 56222285
Constipation 11.14 10.56 267 54715 201676 56035409
Tooth disorder 11.14 10.56 52 54930 25501 56211584
Nerve injury 11.11 10.56 26 54956 8911 56228174
Malabsorption 11.02 10.56 16 54966 3805 56233280
Bone marrow failure 11.02 10.56 7 54975 28279 56208806
Brain herniation 11.01 10.56 15 54967 3365 56233720
Suicidal ideation 10.95 10.56 95 54887 57647 56179438
Postinfarction angina 10.82 10.56 3 54979 28 56237057
Brain oedema 10.80 10.56 33 54949 13238 56223847
Mitral valve prolapse 10.76 10.56 12 54970 2194 56234891
Angioedema 10.60 10.56 15 54967 41438 56195647
Live birth 10.59 10.56 3 54979 19602 56217483

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 489.08 12.25 522 30618 90992 31575212
Toxicity to various agents 277.95 12.25 574 30566 180913 31485291
Accidental overdose 227.62 12.25 169 30971 18181 31648023
Drug abuse 197.42 12.25 328 30812 87430 31578774
Cardio-respiratory arrest 187.10 12.25 242 30898 51484 31614720
Drug dependence 159.15 12.25 150 30990 22429 31643775
Respiratory arrest 138.35 12.25 149 30991 26108 31640096
Drug abuser 114.79 12.25 62 31078 3818 31662386
Off label use 101.94 12.25 115 31025 347159 31319045
Overdose 88.49 12.25 231 30909 84433 31581771
Drug withdrawal syndrome 86.01 12.25 99 31041 18651 31647553
Intentional product misuse 76.14 12.25 135 31005 37816 31628388
Pain 66.63 12.25 360 30780 186399 31479805
Anxiety 65.05 12.25 217 30923 90816 31575388
Depression 64.46 12.25 216 30924 90599 31575605
Inadequate analgesia 63.27 12.25 37 31103 2656 31663548
Emotional distress 56.30 12.25 70 31070 14286 31651918
Cardiac arrest 52.22 12.25 199 30941 88863 31577341
Respiratory depression 49.45 12.25 66 31074 14444 31651760
Drug hypersensitivity 46.55 12.25 167 30973 72432 31593772
Gun shot wound 45.50 12.25 22 31118 1072 31665132
Insomnia 43.11 12.25 196 30944 94640 31571564
Pyrexia 37.79 12.25 162 30978 303678 31362526
Coronary artery disease 36.62 12.25 114 31026 45973 31620231
C-reactive protein increased 36.52 12.25 3 31137 48647 31617557
Back pain 34.35 12.25 204 30936 109209 31556995
Accidental death 33.40 12.25 23 31117 2194 31664010
Ventricular hypertrophy 32.95 12.25 30 31110 4286 31661918
General physical health deterioration 32.64 12.25 38 31102 113397 31552807
Chest pain 32.29 12.25 211 30929 116746 31549458
Myocardial infarction 32.13 12.25 206 30934 113248 31552956
Drug screen positive 31.83 12.25 28 31112 3824 31662380
Drug tolerance 30.69 12.25 23 31117 2504 31663700
Product use in unapproved indication 29.87 12.25 32 31108 99139 31567065
Death 29.77 12.25 508 30632 360061 31306143
Drug interaction 29.18 12.25 106 31034 208437 31457767
Substance abuse 28.22 12.25 35 31105 7123 31659081
Lumbar radiculopathy 27.04 12.25 14 31126 790 31665414
Intervertebral disc degeneration 26.52 12.25 30 31110 5541 31660663
Arteriosclerosis 26.51 12.25 42 31098 10725 31655479
Dependence 25.62 12.25 15 31125 1079 31665125
Cardiac failure 25.59 12.25 28 31112 85925 31580279
Hypoaesthesia 25.59 12.25 116 31024 55906 31610298
Hepatic function abnormal 25.06 12.25 5 31135 41217 31624987
Neutropenia 23.35 12.25 66 31074 140298 31525906
Pain in extremity 23.13 12.25 194 30946 116009 31550195
Spinal osteoarthritis 22.79 12.25 31 31109 6904 31659300
Foetal exposure during pregnancy 22.77 12.25 6 31134 40870 31625334
Renal impairment 22.67 12.25 31 31109 86318 31579886
Poisoning 22.17 12.25 38 31102 10353 31655851
Condition aggravated 21.86 12.25 85 31055 163924 31502280
Interstitial lung disease 21.82 12.25 17 31123 61386 31604818
Back injury 21.09 12.25 22 31118 3710 31662494
Acute kidney injury 20.54 12.25 176 30964 279538 31386666
Intervertebral disc protrusion 20.37 12.25 34 31106 9066 31657138
Arteriosclerosis coronary artery 20.09 12.25 38 31102 11170 31655034
Carpal tunnel syndrome 19.94 12.25 23 31117 4338 31661866
Pulmonary congestion 19.64 12.25 41 31099 12942 31653262
Environmental exposure 19.61 12.25 8 31132 259 31665945
Mental status changes 19.13 12.25 78 31062 35890 31630314
Analgesic drug level 18.69 12.25 5 31135 40 31666164
Antasthmatic drug level 18.69 12.25 5 31135 40 31666164
Gastrooesophageal reflux disease 18.45 12.25 74 31066 33797 31632407
Road traffic accident 18.42 12.25 46 31094 16335 31649869
Hypoxic-ischaemic encephalopathy 18.37 12.25 22 31118 4319 31661885
Febrile neutropenia 18.32 12.25 60 31080 121789 31544415
Leukopenia 18.15 12.25 18 31122 57810 31608394
Rotator cuff syndrome 18.08 12.25 24 31116 5221 31660983
Treatment failure 17.65 12.25 9 31131 40783 31625421
Nervousness 17.54 12.25 37 31103 11763 31654441
COVID-19 17.28 12.25 17 31123 54804 31611400
Cardiomegaly 16.74 12.25 41 31099 14384 31651820
Back disorder 16.73 12.25 25 31115 6068 31660136
Blood cholesterol increased 16.50 12.25 45 31095 16848 31649356
Pulmonary oedema 15.93 12.25 86 31054 44416 31621788
Hyperlipidaemia 15.91 12.25 38 31102 13122 31653082
Walking disability 15.61 12.25 10 31130 845 31665359
Reaction to excipient 15.54 12.25 8 31132 446 31665758
Burning sensation 14.78 12.25 43 31097 16704 31649500
Complex regional pain syndrome 14.59 12.25 8 31132 507 31665697
Coronary artery stenosis 14.59 12.25 29 31111 8841 31657363
Anger 14.35 12.25 33 31107 11120 31655084
Mitral valve incompetence 14.32 12.25 38 31102 13995 31652209
Osteomyelitis 14.29 12.25 39 31101 14604 31651600
Thrombocytopenia 14.29 12.25 82 31058 142665 31523539
Haemorrhoids 14.16 12.25 35 31105 12347 31653857
Thymus disorder 13.89 12.25 3 31137 8 31666196
Liver disorder 13.70 12.25 6 31134 29701 31636503
Product use issue 13.32 12.25 22 31118 56737 31609467
Irritability 13.26 12.25 51 31089 22838 31643366
Phantom limb syndrome 13.13 12.25 6 31134 257 31665947
Neutrophil count decreased 12.84 12.25 16 31124 46378 31619826
Groin pain 12.84 12.25 20 31120 5033 31661171
Drug-induced liver injury 12.79 12.25 4 31136 24359 31641845
Bronchitis 12.65 12.25 73 31067 38644 31627560
Decreased interest 12.56 12.25 13 31127 2172 31664032
Lower respiratory tract infection 12.56 12.25 6 31134 28231 31637973
Oxygen saturation decreased 12.52 12.25 18 31122 49097 31617107
Paraesthesia 12.44 12.25 96 31044 55975 31610229
Radiculopathy 12.41 12.25 14 31126 2578 31663626
Injury 12.32 12.25 45 31095 19664 31646540
Dental caries 12.32 12.25 18 31122 4283 31661921

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1654.37 10.52 1489 63877 225646 70637432
Toxicity to various agents 670.15 10.52 1233 64133 380939 70482139
Cardio-respiratory arrest 542.97 10.52 561 64805 100116 70762962
Cholecystitis chronic 415.40 10.52 193 65173 9183 70853895
Drug abuse 378.00 10.52 565 64801 146691 70716387
Respiratory arrest 335.55 10.52 325 65041 53608 70809470
Accidental overdose 263.56 10.52 235 65131 34886 70828192
Emotional distress 231.07 10.52 224 65142 36964 70826114
Intentional product misuse 214.93 10.52 313 65053 79282 70783796
Drug hypersensitivity 200.93 10.52 614 64752 261845 70601233
Anxiety 182.37 10.52 530 64836 219800 70643278
Injury 178.20 10.52 258 65108 64987 70798091
Off label use 162.96 10.52 272 65094 742788 70120290
Gallbladder disorder 156.17 10.52 130 65236 17582 70845496
Cardiac arrest 151.42 10.52 404 64962 159430 70703648
Drug abuser 146.45 10.52 82 65284 5782 70857296
Depression 145.19 10.52 458 64908 198516 70664562
Cholelithiasis 142.28 10.52 196 65170 47144 70815934
Death 135.04 10.52 867 64499 509194 70353884
Drug dependence 129.83 10.52 166 65200 37155 70825923
Overdose 126.81 10.52 394 64972 169351 70693727
Pain 120.99 10.52 990 64376 627826 70235252
Contraindicated product administered 106.43 10.52 4 65362 134608 70728470
Deep vein thrombosis 100.40 10.52 276 65090 110766 70752312
Drug withdrawal syndrome 99.12 10.52 136 65230 32579 70830499
Biliary dyskinesia 98.89 10.52 47 65319 2352 70860726
Accidental death 98.55 10.52 55 65311 3853 70859225
Synovitis 92.35 10.52 7 65359 129221 70733857
Maternal exposure during pregnancy 89.26 10.52 4 65362 115341 70747737
Infusion related reaction 87.86 10.52 36 65330 197498 70665580
Coronary artery disease 85.79 10.52 183 65183 62553 70800525
Drug intolerance 85.49 10.52 51 65315 225636 70637442
Inadequate analgesia 82.68 10.52 50 65316 4072 70859006
Gallbladder injury 81.48 10.52 33 65333 1119 70861959
Respiratory depression 79.44 10.52 106 65260 24725 70838353
Rheumatoid arthritis 74.26 10.52 96 65270 291709 70571369
C-reactive protein increased 73.57 10.52 8 65358 110509 70752569
Pyrexia 71.72 10.52 302 65064 606650 70256428
Treatment failure 67.86 10.52 24 65342 144118 70718960
Lower respiratory tract infection 65.39 10.52 12 65354 111901 70751177
Hand deformity 63.78 10.52 4 65362 86478 70776600
Drug ineffective 61.30 10.52 563 64803 939189 69923889
Back pain 56.85 10.52 436 64930 270716 70592362
Neutropenia 54.39 10.52 96 65270 257060 70606018
Joint swelling 53.13 10.52 95 65271 253116 70609962
Chest pain 52.65 10.52 404 64962 250856 70612222
Insomnia 50.05 10.52 358 65008 217448 70645630
Poisoning 49.81 10.52 81 65285 22541 70840537
Pulmonary embolism 48.02 10.52 276 65090 155591 70707487
Systemic lupus erythematosus 47.90 10.52 17 65349 101885 70761193
Product use in unapproved indication 47.07 10.52 74 65292 207404 70655674
Cardiac failure 46.95 10.52 38 65328 143503 70719575
Febrile neutropenia 46.23 10.52 73 65293 204245 70658833
Gallbladder hypofunction 45.93 10.52 17 65349 450 70862628
Pericarditis 45.54 10.52 11 65355 84694 70778384
Glossodynia 45.02 10.52 12 65354 86475 70776603
Mental status changes 43.88 10.52 143 65223 62958 70800120
Gun shot wound 42.90 10.52 21 65345 1122 70861956
Myocardial infarction 42.88 10.52 288 65078 171357 70691721
Drug screen positive 41.66 10.52 38 65328 5802 70857276
Interstitial lung disease 40.54 10.52 23 65343 104662 70758416
Renal impairment 40.15 10.52 44 65322 143893 70719185
Cerebrovascular accident 39.05 10.52 246 65120 143224 70719854
Rash 38.98 10.52 293 65073 510269 70352809
Drug interaction 38.91 10.52 200 65166 381241 70481837
Condition aggravated 38.84 10.52 233 65133 427402 70435676
Drug tolerance 37.47 10.52 40 65326 7388 70855690
Helicobacter infection 37.10 10.52 4 65362 55652 70807426
Hypersensitivity 36.10 10.52 101 65265 229711 70633367
Pain in extremity 36.00 10.52 461 64905 327621 70535457
Exposure during pregnancy 35.83 10.52 18 65348 87699 70775379
Nasopharyngitis 35.39 10.52 97 65269 222109 70640969
Hepatic function abnormal 34.33 10.52 10 65356 67986 70795092
Thrombocytopenia 34.03 10.52 110 65256 239000 70624078
Leukopenia 33.87 10.52 29 65337 106531 70756547
Scar 33.45 10.52 52 65314 13929 70849149
Cholestasis 33.07 10.52 3 65363 47869 70815209
Product use issue 33.00 10.52 73 65293 179864 70683214
Gamma-glutamyltransferase increased 32.89 10.52 4 65362 50681 70812397
Biliary colic 32.35 10.52 27 65339 3663 70859415
Intervertebral disc protrusion 32.04 10.52 65 65301 21438 70841640
Anhedonia 31.44 10.52 51 65315 14162 70848916
Hepatic enzyme increased 31.05 10.52 61 65305 156929 70706149
Rheumatoid factor positive 30.97 10.52 4 65362 48396 70814682
Gastrooesophageal reflux disease 30.72 10.52 165 65201 90674 70772404
Ventricular hypertrophy 30.67 10.52 34 65332 6550 70856528
Arteriosclerosis 30.60 10.52 55 65311 16583 70846495
Back injury 30.36 10.52 39 65327 8763 70854315
Drug reaction with eosinophilia and systemic symptoms 30.28 10.52 8 65358 58005 70805073
Gallbladder cholesterolosis 29.33 10.52 13 65353 553 70862525
Dependence 29.28 10.52 21 65345 2279 70860799
Acute kidney injury 29.22 10.52 288 65078 474336 70388742
Hyperlipidaemia 28.54 10.52 66 65300 23797 70839281
Substance abuse 28.45 10.52 40 65326 9797 70853281
Road traffic accident 28.19 10.52 83 65283 34599 70828479
Cholesterosis 27.70 10.52 11 65355 354 70862724
Muscle spasms 27.53 10.52 239 65127 153807 70709271
General physical health deterioration 27.43 10.52 118 65248 235913 70627165
Feeling abnormal 27.12 10.52 224 65142 142095 70720983
Uterine perforation 26.72 10.52 30 65336 5861 70857217
Wound 26.64 10.52 31 65335 98701 70764377
Eosinophilia 26.62 10.52 3 65363 40316 70822762
Toxic epidermal necrolysis 25.97 10.52 3 65363 39554 70823524
Cholecystectomy 25.24 10.52 35 65331 8462 70854616
Erythema 24.92 10.52 97 65269 199466 70663612
Nervousness 24.84 10.52 74 65292 31046 70832032
Hyponatraemia 24.65 10.52 71 65295 160016 70703062
Rotator cuff syndrome 24.58 10.52 43 65323 12691 70850387
Cholecystitis 24.48 10.52 57 65309 20644 70842434
Discomfort 24.47 10.52 37 65329 105399 70757679
Intervertebral disc degeneration 24.36 10.52 45 65321 13855 70849223
COVID-19 23.70 10.52 38 65328 105719 70757359
Arteriosclerosis coronary artery 22.97 10.52 48 65318 16167 70846911
Lactic acidosis 22.81 10.52 16 65350 65008 70798070
Rash maculo-papular 22.80 10.52 9 65357 50536 70812542
Muscle injury 22.75 10.52 4 65362 38490 70824588
Liver injury 22.71 10.52 5 65361 41030 70822048
Infection 22.33 10.52 109 65257 210676 70652402
Memory impairment 22.26 10.52 154 65212 92487 70770591
Drug-induced liver injury 22.20 10.52 12 65354 56101 70806977
Coronary artery stenosis 22.06 10.52 39 65327 11605 70851473
Peripheral vascular disorder 22.02 10.52 31 65335 7601 70855477
Inflammation 21.98 10.52 24 65342 78641 70784437
Folliculitis 21.97 10.52 6 65360 42564 70820514
Hypoaesthesia 21.74 10.52 227 65139 153512 70709566
Blood pressure systolic increased 21.57 10.52 13 65353 57246 70805832
Acute lung injury 21.46 10.52 19 65347 2790 70860288
Mental disorder 21.46 10.52 66 65300 28174 70834904
Stomatitis 21.28 10.52 55 65311 128456 70734622
Tarsal tunnel syndrome 21.14 10.52 10 65356 495 70862583
Hepatocellular injury 21.13 10.52 8 65358 46083 70816995
Hyperkalaemia 20.57 10.52 42 65324 106549 70756529
Liver disorder 20.50 10.52 16 65350 61552 70801526
Drug resistance 20.45 10.52 5 65361 38185 70824893
Pulmonary congestion 20.25 10.52 60 65306 25094 70837984
Septic shock 20.20 10.52 46 65320 112212 70750866
Spinal osteoarthritis 20.09 10.52 44 65322 15304 70847774
Chronic obstructive pulmonary disease 19.80 10.52 131 65235 77510 70785568
Migraine 19.72 10.52 124 65242 72114 70790964
Back disorder 19.53 10.52 35 65331 10529 70852549
Therapeutic product effect decreased 19.50 10.52 67 65299 142951 70720127
Thrombosis 19.10 10.52 127 65239 75278 70787800
Epilepsy 19.04 10.52 6 65360 38778 70824300
Antasthmatic drug level 19.00 10.52 5 65361 40 70863038
Mitral valve incompetence 18.96 10.52 61 65305 26667 70836411
Blood pressure fluctuation 18.82 10.52 16 65350 58996 70804082
Lumbar radiculopathy 18.79 10.52 15 65351 1911 70861167
Neutrophil count decreased 18.74 10.52 30 65336 83526 70779552
Bone marrow failure 18.64 10.52 11 65355 48999 70814079
Analgesic drug level 18.58 10.52 5 65361 44 70863034
Emotional disorder 18.55 10.52 39 65327 13187 70849891
Sleep disorder due to general medical condition, insomnia type 18.51 10.52 5 65361 35727 70827351
Multiple organ dysfunction syndrome 18.31 10.52 46 65320 108469 70754609
Altered state of consciousness 18.26 10.52 7 65359 40015 70823063
Pneumocystis jirovecii pneumonia 18.06 10.52 3 65363 30079 70832999
Purpura senile 18.02 10.52 9 65357 502 70862576
Angina unstable 17.96 10.52 43 65323 15850 70847228
Environmental exposure 17.58 10.52 8 65358 362 70862716
Cardiomegaly 17.39 10.52 56 65310 24489 70838589
Carpal tunnel syndrome 17.02 10.52 44 65322 17013 70846065
Oxygen saturation decreased 16.94 10.52 53 65313 116376 70746702
Electrocardiogram QT prolonged 16.90 10.52 32 65334 83485 70779593
Pancytopenia 16.66 10.52 77 65289 151030 70712048
Fear 16.15 10.52 49 65317 20762 70842316
Melaena 15.96 10.52 17 65349 56338 70806740
Transaminases increased 15.93 10.52 12 65354 47006 70816072
Accident 15.90 10.52 26 65340 7265 70855813
Intervertebral disc disorder 15.32 10.52 20 65346 4565 70858513
Chronic fatigue syndrome 15.20 10.52 11 65355 1211 70861867
Amnesia 15.17 10.52 91 65275 52064 70811014
Withdrawal syndrome 15.16 10.52 54 65312 24850 70838228
Postinfarction angina 14.89 10.52 4 65362 35 70863043
Angioedema 14.86 10.52 24 65342 66586 70796492
Obstructive airways disorder 14.82 10.52 3 65363 26110 70836968
Multiple injuries 14.76 10.52 17 65349 3414 70859664
Peptic ulcer 14.73 10.52 22 65344 5691 70857387
Irritability 14.71 10.52 72 65294 38153 70824925
Extradural haematoma 14.41 10.52 15 65351 2690 70860388
Anaphylactic shock 14.30 10.52 6 65360 32484 70830594
Major depression 14.08 10.52 27 65339 8547 70854531
Anaphylactic reaction 14.08 10.52 30 65336 74944 70788134
Sepsis 13.94 10.52 151 65215 244394 70618684
Lymphopenia 13.85 10.52 4 65362 27355 70835723
Crying 13.80 10.52 47 65319 21152 70841926
Copper deficiency 13.59 10.52 5 65361 130 70862948
Drug eruption 13.48 10.52 10 65356 39486 70823592
Pulmonary oedema 13.33 10.52 125 65241 82153 70780925
Nausea 13.27 10.52 933 64433 851155 70011923
Transient ischaemic attack 13.25 10.52 80 65286 45864 70817214
Hypoxic-ischaemic encephalopathy 13.24 10.52 24 65342 7284 70855794
Respiratory disorder 13.24 10.52 10 65356 39113 70823965
Heart rate decreased 13.23 10.52 23 65343 61992 70801086
Pulmonary infarction 13.14 10.52 16 65350 3407 70859671
Cholecystitis acute 13.07 10.52 32 65334 11962 70851116
Asthma 13.05 10.52 62 65304 120731 70742347
Respiratory muscle weakness 12.94 10.52 6 65360 284 70862794
Opiates positive 12.93 10.52 9 65357 931 70862147
Red blood cell sedimentation rate increased 12.92 10.52 10 65356 38632 70824446
Wheezing 12.91 10.52 44 65322 94126 70768952
Unresponsive to stimuli 12.87 10.52 87 65279 51844 70811234
Brain oedema 12.77 10.52 49 65317 23369 70839709
Platelet count decreased 12.75 10.52 104 65262 178118 70684960
Urticaria 12.67 10.52 93 65273 162956 70700122
Cardiogenic shock 12.65 10.52 9 65357 36298 70826780
Accidental poisoning 12.52 10.52 11 65355 1599 70861479
Hernia 12.49 10.52 36 65330 14824 70848254
Toxic leukoencephalopathy 12.43 10.52 9 65357 991 70862087
Head injury 12.21 10.52 63 65303 34078 70829000
Hepatitis 12.12 10.52 17 65349 49963 70813115
Neuropathy peripheral 12.11 10.52 174 65192 126722 70736356
Malabsorption 12.06 10.52 18 65348 4652 70858426
Neck injury 12.02 10.52 13 65353 2437 70860641
Laryngeal pain 11.92 10.52 20 65346 5708 70857370
Resorption bone increased 11.86 10.52 10 65356 1375 70861703
Gross motor delay 11.86 10.52 4 65362 80 70862998
Therapeutic product effect increased 11.82 10.52 10 65356 1382 70861696
Post concussion syndrome 11.82 10.52 7 65359 549 70862529
Muscle atrophy 11.66 10.52 28 65338 10342 70852736
Product complaint 11.64 10.52 31 65335 12200 70850878
Phantom limb syndrome 11.62 10.52 6 65360 359 70862719
Musculoskeletal stiffness 11.61 10.52 84 65282 147676 70715402
Anger 11.61 10.52 37 65329 16095 70846983
Peripheral swelling 11.59 10.52 151 65215 236412 70626666
Osteomyelitis 11.59 10.52 57 65309 30261 70832817
Cardiac failure congestive 11.48 10.52 182 65184 135275 70727803
Complex regional pain syndrome 11.47 10.52 11 65355 1789 70861289
Arthropathy 11.46 10.52 86 65280 149971 70713107
Tooth loss 11.45 10.52 21 65345 6429 70856649
Acute myocardial infarction 11.44 10.52 110 65256 72777 70790301
Snake bite 11.40 10.52 3 65363 24 70863054
Blood creatinine increased 11.38 10.52 81 65285 142920 70720158
Coronary artery occlusion 11.34 10.52 34 65332 14311 70848767
Myofascial pain syndrome 11.25 10.52 11 65355 1831 70861247
Tendon disorder 11.22 10.52 21 65345 6530 70856548
Stevens-Johnson syndrome 11.13 10.52 10 65356 35897 70827181
Transverse sinus thrombosis 11.09 10.52 7 65359 615 70862463
Polyneuropathy 11.09 10.52 3 65363 21412 70841666
Chronic kidney disease 11.04 10.52 95 65271 60962 70802116
Blood pressure diastolic decreased 10.97 10.52 5 65361 25775 70837303
Neurotoxicity 10.92 10.52 7 65359 29819 70833259
Circulatory collapse 10.85 10.52 10 65356 35464 70827614
Bronchopulmonary aspergillosis 10.76 10.52 3 65363 20999 70842079
Paraesthesia 10.67 10.52 191 65175 145346 70717732
Endometriosis 10.63 10.52 14 65352 3222 70859856
Cerebral haemorrhage 10.58 10.52 21 65345 53843 70809235
Dyspepsia 10.52 10.52 127 65239 88950 70774128

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05DA03 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
Opium alkaloids and derivatives
FDA MoA N0000000174 Opioid Agonists
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D000996 Antitussive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35482 narcotic analgesic
CHEBI has role CHEBI:51177 anti-tussive
CHEBI has role CHEBI:55322 mu-opioid agonists
FDA EPC N0000175690 Opioid Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Rhinitis indication 70076002 DOID:4483
Common cold indication 82272006 DOID:10459
Brain damage contraindication 2470005
Ocular hypertension contraindication 4210003 DOID:9282
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Hyperkalemia contraindication 14140009
Severe chronic ulcerative colitis contraindication 14311001
Constipation contraindication 14760008 DOID:2089
Mood swings contraindication 18963009
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ventricular tachycardia contraindication 25569003
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hypercapnia contraindication 29596007
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Gastrointestinal perforation contraindication 51875005
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Blood coagulation disorder contraindication 64779008 DOID:1247
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Urethral stricture contraindication 76618002
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Hiatal hernia contraindication 84089009 DOID:12642
Pulmonary emphysema contraindication 87433001
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Myasthenia gravis contraindication 91637004 DOID:437
Anemia due to enzyme deficiency contraindication 111577008
Acute abdominal pain contraindication 116290004
Gastrointestinal obstruction contraindication 126765001
Neoplasm of brain contraindication 126952004 DOID:1319
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Drug-induced psychosis contraindication 191483003 DOID:1742
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Coronary artery bypass graft contraindication 232717009
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Hyporeninemic hypoaldosteronism contraindication 236464008
Bladder outflow obstruction contraindication 236645006
Morbid obesity contraindication 238136002 DOID:11981
Rhabdomyolysis contraindication 240131006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Exacerbation of asthma contraindication 281239006
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Central nervous system depression contraindication 418072004
Dysfunction of sphincter of Oddi contraindication 430887001
Hypertensive urgency contraindication 443482000
Acute erosive gastritis contraindication 444926003
Smokes tobacco daily contraindication 449868002
Acute Thromboembolic Stroke contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 10130591 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8309060 Nov. 20, 2023 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 11304909 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9095614 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492390 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9492391 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 9545380 Aug. 24, 2027 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG HYSINGLA ER PURDUE PHARMA LP N206627 Nov. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 8808740 Dec. 21, 2031 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10028946 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10456393 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10722511 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9265760 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9326982 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9333201 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9339499 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9421200 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9433619 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9610286 July 25, 2033 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
10MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
15MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
20MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
30MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
40MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 10092559 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9452163 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9486451 Sept. 12, 2034 TREATMENT OF PAIN
50MG ZOHYDRO ER RECRO GAINESVILLE N202880 Oct. 25, 2013 DISCN CAPSULE, EXTENDED RELEASE ORAL 9713611 Sept. 12, 2034 TREATMENT OF PAIN
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 10105324 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 9549907 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML OBREDON SOVEREIGN PHARMS N205474 Nov. 14, 2014 DISCN SOLUTION ORAL 9808431 Nov. 13, 2035 A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 8.02 CHEMBL CHEMBL
Kappa-type opioid receptor GPCR AGONIST Ki 6.59 CHEMBL

External reference:

IDSource
4018165 VUID
N0000146502 NUI
D03725 KEGG_DRUG
34195-34-1 SECONDARY_CAS_RN
4018165 VANDF
4018473 VANDF
4019409 VANDF
C0020264 UMLSCUI
CHEBI:5779 CHEBI
CHEMBL1457 ChEMBL_ID
DB00956 DRUGBANK_ID
CHEMBL3989677 ChEMBL_ID
CHEMBL2062267 ChEMBL_ID
D006853 MESH_DESCRIPTOR_UI
5284569 PUBCHEM_CID
7081 IUPHAR_LIGAND_ID
1700 INN_ID
6YKS4Y3WQ7 UNII
142439 RXNORM
13945 MMSL
4835 MMSL
4836 MMSL
d03075 MMSL
001554 NDDF
001555 NDDF
001556 NDDF
20320002 SNOMEDCT_US
372671002 SNOMEDCT_US
3874004 SNOMEDCT_US
736862006 SNOMEDCT_US
CHEMBL1201470 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-0772 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-0772 SOLUTION 7.50 mg ORAL ANDA 30 sections
Zamicet HUMAN PRESCRIPTION DRUG LABEL 2 0121-1542 SOLUTION 5 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-1544 SOLUTION 5 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-1544 SOLUTION 5 mg ORAL ANDA 30 sections
Zamicet HUMAN PRESCRIPTION DRUG LABEL 2 0121-2313 SOLUTION 10 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-2316 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-2316 SOLUTION 7.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-4772 SOLUTION 2.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0121-4772 SOLUTION 2.50 mg ORAL ANDA 30 sections
Hydrocodone Bitartrate and Homatropine Methylbromide HUMAN PRESCRIPTION DRUG LABEL 2 0121-4811 SYRUP 5 mg ORAL ANDA 35 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0054 CAPSULE, EXTENDED RELEASE 5 mg ORAL ANDA 24 sections
TussiCaps HUMAN PRESCRIPTION DRUG LABEL 2 0187-0108 CAPSULE, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0410 TABLET 5 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0411 TABLET 7.50 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0245-0412 TABLET 10 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2034 TABLET 5 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2035 TABLET 7.50 mg ORAL ANDA 34 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0254-2036 TABLET 10 mg ORAL ANDA 34 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0123 TABLET 5 mg ORAL ANDA 28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0124 TABLET 7.50 mg ORAL ANDA 28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0406-0125 TABLET 10 mg ORAL ANDA 28 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0406-0376 TABLET 5 mg ORAL ANDA 27 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0406-0377 TABLET 7.50 mg ORAL ANDA 27 sections
Hydrocodone Bitartrate and Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0406-0378 TABLET 10 mg ORAL ANDA 27 sections
Hydrocodone Bitartrate And Acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0440-7605 TABLET 5 mg ORAL ANDA 30 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN HUMAN PRESCRIPTION DRUG LABEL 2 0440-7610 TABLET 5 mg ORAL ANDA 27 sections
Hydromet HUMAN PRESCRIPTION DRUG LABEL 2 0472-1030 SOLUTION 5 mg ORAL ANDA 29 sections
Hydromet HUMAN PRESCRIPTION DRUG LABEL 2 0472-1030 SOLUTION 5 mg ORAL ANDA 29 sections
Zamicet HUMAN PRESCRIPTION DRUG LABEL 2 0486-0771 SOLUTION 10 mg ORAL ANDA 30 sections